Abstract
The prevalence of diabetes is higher amongst individuals infected with HIV. The major contributor to hyperglycaemia is thought to be iatrogenic, with protease inhibitors being most commonly associated to insulin resistance. This article is to update general practitioners on the diagnosis and management of diabetes in HIV-infected patients. Specific considerations are highlighted including interactions of particular diabetic drugs with antiretroviral therapy (ART). We articulate why the use of Hemoglobin A1c (HbA1c) testing is not recommended as a diagnostic tool.
Highlights
The prevalence of diabetes is higher amongst individuals infected with HIV
(3) Hemoglobin A1c (HbA1c) is not recommended for screening for diabetes in HIV infected individuals
A recent study has shown that diabetes is up to four fold more common in HIV-infected men exposed to Highly Active Anti-Retroviral Therapy (HAART) than in HIV seronegative men [1]
Summary
A recent study has shown that diabetes is up to four fold more common in HIV-infected men exposed to Highly Active Anti-Retroviral Therapy (HAART) than in HIV seronegative men [1]. The HIV lipodystrophy syndrome is characterised by insulin resistance, an abnormal lipid profile and peripheral fat wasting with central fat (visceral) accumulation. Diabetes due to HIV disease Endocrine abnormalities
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
